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Abstract
Cytokine receptors are transmembrane proteins that transmit a signal into the cell upon ligand binding. Commonly, these molecules have
one hydrophobic segment of about 20–26 amino acids that is believed to span the membrane as a helix and this divides these receptors into
extra- and intracellular components. By utilizing two different epitopes, the cytokines bridge two receptor chains, resulting in a close
proximity of the intracellular component and thereby initiating the intracellular signalling cascade. The dimerization event is believed to be
the mechanism by which the signal is transmitted across a membrane. In the light of new results obtained for the erythropoietin receptor,
James A. Wells questioned whether any dimer would be sufficient. This review will expand upon the above question by discussing the more
complex signal-transducing receptor subunits of the Interleukin-6 type family of cytokines. Based on the recently solved quaternary structure
of the Insulin receptor, possible analogies will be confronted.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Information in an organism is transmitted by the inter-
action between molecules. Proteins and the formation of
protein complexes play a central role in cell communication.
The flow of information is organized in signalling cascades
which are initiated by the interaction of a ligand with a
membrane-spanning receptor. Upon ligand binding, these
receptors become activated and thereby transmit the signal
from the outside to the inside of a cell where a cascade of
events is initiated. This cascade is complex and not fully
understood so far. The intrinsic regulation and even the
crosstalk between different signal-transducing pathways
have been studied extensively during the last years. These
cascades mostly involve several phosphorylation/dephos-
phorylation events that result in protein activation, enzy-
matic activity or susceptibility for interaction with other
proteins. The initial ligand/receptor interaction seems to be
the most specific step. The specificity of ligand/receptor
interaction has been well studied in the field of cytokines
and their receptors [1–3].
The growth hormone (GH) receptor complex was the
first four-helical cytokine receptor to be crystallized together
with its ligand [4] and has therefore become paradigmatic
for the understanding of four-helical cytokine receptor
complexes. One GH molecule binds to two receptor mole-
cules via two contact epitopes designated as site I and site II.
Remarkably, the two receptors use identical amino acid
residues to bind the two different epitopes of the cytokine
[4,5]. One paradigmatic conclusion derived from these
studies is that generally cytokines are recognized by their
cognate receptors at sites equivalent to site I and site II of
GH [3,4]. The X-ray structure of the viral Interleukin-6/
gp130 complex revealed that this paradigm does not fully
explain the situation in IL-6 type cytokines as biochemical
studies have demonstrated the existence of a site III on IL-6
and the activation of gp130 requires two distinct binding
epitopes on the receptor [6–12]. This structural information
not only contributed remarkably to the understanding of
protein/protein interactions but also provided the basis for
the design of new cytokines and deliberate manipulation of
cytokine signalling. The fact that at least two receptors are
needed to induce signalling has led to the assumption that
receptor dimerization is the crucial step for transmitting the
signal through the membrane. For the erythropoietin recep-
tor it has been shown that dimerization is indispensable but
not sufficient for activation [13–16]. Besides dimerization,
a specific orientation of the involved receptor chains seems
to be mandatory [16,17]. In cases where receptors already
0167-4889/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0167 -4889 (02 )00316 -6
* Tel.: +49-431-880-1686; fax: +49-431-880-5007.
E-mail address: jgroetzinger@biochem.uni-kiel.de (J. Gro¨tzinger).
www.bba-direct.com
Biochimica et Biophysica Acta 1592 (2002) 215–223
exist as preformed dimers, ligand binding might replace
binding sites engaged in the formation of such dimers and
thereby changing their orientation. This review will focus on
cytokine receptors and their dimerization as one mechanism
for the transmission of information across a membrane.
2. Results and discussion
2.1. The cytokines
More than a decade ago, Fernando Bazan presented two
seminal papers in which he suggested that known cytokines
shared a common protein fold [18,19]. This work was
mainly based on theoretical considerations and grouped
these proteins into the family of ‘‘four-helix bundle’’ cyto-
kines. These four helices are arranged in an up-up-down-
down topology (Fig. 1A), which as yet has not been
identified in any other non-cytokine protein and is therefore
to be regarded as the typical cytokine fold. This topology
demands that the three loops connecting the four helices are
long-short-long.
All these cytokines transmit their signal into the cell by
multi-subunit receptor complexes. Subfamilies of cytokines
have been defined based on the fact that certain signal-
transducing receptor subunits are shared between them. One
of such receptor-subunits is gp130 which is shared by the
Interleukin-6 (IL-6) type cytokines (IL-6, IL-11, ciliary
neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardi-
otrophin-1 like cytokine (CLC), leukemia inhibitory factor
(LIF), oncostatin M (OSM)) as part of the signal-trans-
ducing complex. Similarly, the h-subunit of the IL-3 recep-
tor is shared by IL-3, IL-5 and granulocyte macrophage
colony stimulating factor (GM-CSF), whilst the IL-2g
receptor is the common subunit for IL-2, IL-4, IL-7 and
IL-15 (see Table 1). Another possibility to allocate all these
cytokines (IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10,
IL-11, the p35 subunit of IL-12, IL-13, IL-15, granulocyte
colony stimulating factor (G-CSF), GM-CSF, erythropoietin
(EPO), GH, prolactin (PRL), CNTF, CT-1, CLC, LIF, OSM,
interferon a (IFNa) and IFNg) [20,21] into subfamilies is
based on structural considerations and has been suggested
by Bazan. This classification divides the cytokines into
short-chain (IL-3, IL-4, IL-5, IL-15 and GM-CSF) or
long-chain cytokines (the remainder) [22]. The so far known
3D structures solved by crystallography or NMR of these
cytokines have confirmed Bazan’s landmark prediction
(Table 2). As new cytokines are still being identified there
may be other possibilities to define subfamilies. One such
possibility is the number of different receptors engaged in
the final signal-transducing receptor complex, which is
tantamount to the number of interaction epitopes present
on the corresponding cytokine. As an example, GH, EPO or
IL-4 have two ligand/receptor interaction sites, whereas
cytokines like CNTF, IL-11, IL-15 and IL-6 have three
[4,23,24]. These sites were designated I, II and III (Fig. 1B).
The use of a different number of epitopes and their relative
orientation to each other raises the questions (1) whether the
mechanism by which the signal is transmitted into the cell is
also different and (2) to what extent the topology of the
receptors, here defined as the relative orientation of domains
to each other, plays a role in this process.
2.2. Structural complexity of receptors
Type I cytokine receptors are proteins spanning the
cellular membrane with their NH2 terminus at the extrac-
ellular and the C terminus at the intracellular side. The
extracellular part is responsible for the interaction with a
ligand. The intracellular part exhibits either intrinsic kinase
activity or contains the so-called adapter domains, which are
Fig. 1. The ‘four helix bundle’ cytokines. (A) Schematic representation of
the ‘four helix bundle’ cytokines with an up-up-down-down topology. The
four helices are designated as: A, B, C, and D. (B) A ribbon representation
of the Interleukin-6 structure solved by NMR spectroscopy [49]. The
interaction epitopes with the different receptor subunits (site I: IL-6R, site
II: gp130 cytokine receptor homology region (CRH) and site III: gp130 Ig-
like domain) are encircled and marked.
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able to interact with kinases. In both instances, binding of a
ligand to the extracellular part initiates the intracellular
signalling cascade. Almost all molecules involved in these
cascades show a modular architecture, i.e. they consist of
several domains. These domains are either enzymes, like
kinases, phosphatases or proteases, and/or consist of several
docking modules responsible for the interaction with other
molecules of the signalling cascade. As an example, the
insulin receptor (INSR) contains an intrinsic kinase and the
signal transducers of cytokines, like gp130, EpoR, GHR and
IL-4R, are constitutively associated with tyrosine kinases of
the Janus-kinase (Jak) family [25,26]. In contrast, the tumor
necrosis factor receptor (TNFR)-1 and -2 show neither
intrinsic enzymatic activity nor are they directly associated
with enzymes. Although activated by the same ligand, they
initiate different signalling cascades depending on their
different intracellular modules. The intracellular death
domain of the TNFR1 interacts with proteins named
TRADD that leads to the activation of a series of proteases
belonging to the caspase family. The TNFR2 does not
contain a death domain but interacts with the FADD protein
(for review see Ref. [27]).
Like the intracellular parts, the extracellular portions of
cytokine receptors are built up by modules. Some of these
modules are found in several receptor superfamilies. In the
following, I will focus on the TNFR superfamily, the
insulin/insulin-like receptors and the 4-helical cytokine-
receptor superfamily. For example, the extracellular part of
the TNFR consists of four cysteine-rich regions [28]. Three
of these repeats are also found in the INSR where they are
flanked by the so-called L1 and L2 domains (see Fig. 2)
[29]. In addition to these three domains, which are respon-
sible for ligand binding, this receptor contains three mem-
brane proximal domains sharing the fibronectin type III
(FNIII) fold [30]. This architecture is also present in the
signal-transducing receptor subunits of the IL-6 type family
of cytokines namely gp130, LIFR and OSMR (see Fig. 2)
[19,22]. These belong to the family of cytokine receptors
which is defined by the presence of the so-called cytokine-
receptor homology region (CRH) consisting of two immu-
noglobulin domains, whereby the loops connecting the h-
sheets establish the specific contact to the ligand [1]. The
membrane proximal immunoglobulin domain contains a
typical sequence motif tryptophan-serine-X-tryptophan-ser-
ine (WSXWS) in which X can be any amino acid residue.
The above described receptors can be divided into two
classes with respect to their complexity. For the remainder
of this review receptors like GHR, EpoR and IL-4R, which
contain only domains in the extracellular region that are
involved in ligand binding, are called ‘simple’ receptors.
Receptors like gp130, G-CSFR and INSR, which contain
additional domains apparently not involved in ligand bind-
ing, are designated as ‘complex’ receptors.
2.3. ‘Simple’ receptors
The class of ‘simple’ receptors can be further subdivided
into two groups, which either homo- or heterodimerize upon
ligand binding. Examples of ligands for these receptors are
GH or IL-4, respectively, and they differ in the mode of
interaction with the receptors [5,31]. The GH receptor
complex is depicted in Fig. 3. One GH molecule binds
two receptor molecules via two contact epitopes designated
site I and II. Remarkably, the two receptors use identical
amino acid residues to bind the two different epitopes of the
cytokine [4,5,32]. However, the two interaction sites differ
in their free energy of binding. One paradigmatic conclusion
derived from these studies was that cytokines generally are
recognized by their cognate receptors at sites equivalent to
sites I and II of GH [4,32]. A detailed analysis of the
interaction epitopes suggested a common design [4,5].
Using an alanine scan, in which all residues in the inter-
action area have been mutated to alanine, the contribution of
each amino acid residue to the binding energy has been
Table 1
Receptor sharing by cytokines
Cytokines a-Receptora h1-Receptorb h2-Receptorb
IL-6 IL-6R gp130 gp130
IL-11 IL-11R gp130 gp130
CNTF CNTFR gp130 LIFR
CLC CNTFR gp130 LIFR
CT-1 (?) gp130 LIFR
OSM gp130 LIFR or OSMR
LIF gp130 LIFR
IL-3 IL-3R IL-3h
IL-5 IL-5R IL-3h
GM-CSF GM-CSFR IL-3h
IL-2 IL-2Ra IL-2Rb IL-2Rg
IL-4 IL-4R or IL-13R IL-2Rg
IL-7 IL-7R IL-2Rg
IL-15 IL-15Ra IL-2Rh IL-2Rg
a a-Receptors are defined as non-signalling ligand binding receptor
subunits.
b h-Receptors are defined as signalling receptor subunits.
Table 2
Overview of known cytokine, cytokine-receptor and cytokine/cytokine-
receptor structures
Cytokines Cytokine receptors Cytokine/cytokine-
receptor complexes
Long chain IL-2 [47] gp130 (D2-D3) [57] GH/(GHR)2 [4]
IL-6 [48,49] gp130 (D3) [58] GH/PRLR [62]
IL-10 [50] EpoR [13] IL-4/IL-4-R [31]
CNTF [51] G-CSFR (D3) [59] EPO/(EpoR)2 [17]
LIF [52] IL-3Rh [60,61] G-CSF/GCSFR [63]
G-CSF [53] IL-12a/IL-12h [64]
EPO [54] (viral-IL-6)2/
GH [55] (gp130)2 [6]
OSM [56]
Short chain IL-3 [65]
IL-4 [66,67]
IL-5 [68]
IL-13 [69]
GM-CSF [70]
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studied. Hydrophobic residues, aliphatic parts of polar side
chains and parts of the backbone were involved in the most
important interactions. This hydrophobic core is surrounded
by a region consisting of polar and charged amino acid
residues which only slightly contribute to the binding
energy, but are involved in the specific recognition of the
two molecules [5]. In contrast to this architecture, the IL-4/
IL-4R interaction epitopes have been described as ‘avocado
clusters’, where a nucleus is also enveloped by an oily shell
[31]. Instead of having a hydrophobic core, the central
interaction is mediated by charged side chains or amino
acid residues capable of forming hydrogen bonds. This
central area is surrounded by a shell of hydrophobic amino
acids [31].
Fig. 3. The growth hormone receptor complex. Ribbon representation of the X-ray structure of the GH (green) and GHR (red and blue) complex [4]. The two
receptor chains bind one molecule of GH via sites I and II.
Fig. 2. Receptors sharing common extracellular modules. Schematic representations of the domains present in the extracellular parts of the Insulin receptor
(INSR), gp130 and the human growth hormone receptor (GHR) as examples for ‘complex’ and ‘simple’ receptors, respectively. The cysteine bridges are
depicted in green, arrows mark the cleavage site between the a- and h-sub-units in the insulin pro-receptor. TK: intrinsic tyrosine kinase domain of the insulin
receptor; Jak: Janus-kinases; L1, CR, L2, Fn0, Fn1, Fn2: insulin receptor domains; D1, D2, D3, D4, D5, D6: gp130 domains.
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Regardless of the specific mode of interaction, GH and
IL-4 were thought to cause dimerization of the receptor
chains by bringing the intracellular parts in close proximity
and thereby initiating the intracellular signalling cascade.
Therefore, it appeared that dimerization is needed and
sufficient for the onset of the signal transduction.
Most interestingly, it has been shown that dimerization is
needed but not sufficient for some of the homodimeric
receptors and that they exist as preformed dimers on the
cell surface. Crystallographic and biochemical studies have
demonstrated that the EpoR as well as the TNFR-1 are
dimers even in the absence of their ligands [13,33].
Although the X-ray structure of the TNF/TNFR-1 com-
plex consists of a trimeric ligand bound to a trimeric
receptor, the unliganded receptor forms dimers [33,34].
Further biochemical data support the idea that a dimeriza-
tion of the TNFR-1 is sufficient to initiate signal trans-
duction and that the trimeric form of the complex seen in the
crystal structure might not reflect the situation on the cell
surface [35].
In the case of the EpoR, there is crystallographic evi-
dence for preformed dimers of this receptor. Distinct dimeric
configurations exist for this receptor dependent on being
unliganded, Epo bound or bound to agonistic or antagonistic
peptides [13,14,16]. The presence of a ligand and its agonist
or antagonist activity resulted in different distances and
orientations of the receptor parts close to the membrane
[14].
Furthermore, in vivo fragment complementation assays
were used to study this allosteric model of receptor
activation. Complementary fragments of the enzyme dihy-
drofolate reductase were fused to the intracellular part of
EpoR and bind a fluorescein-conjugated inhibitor metho-
trexate (fMTX) during reassembling inside the cell. The
fMTX is retained in cells by this complex whereas
unbound fMTX is actively transported out of the cells
[36]. The fMTX–DHFR complexes can then be monitored
by fluorescence. These sophisticated experiments revealed
that unliganded receptor dimers exist in a configuration
that prevents activation of the signalling cascade but they
can undergo a ligand-induced change in the orientation of
the two receptors that allows activation of the involved
intracellular kinases [16].
Beyond the evidence that preformed dimers exist, the
structures of the unliganded receptors revealed that the
dimerization occurs via epitopes that are also involved in
ligand binding [13]. Therefore, ligand binding to these
receptors might be regarded as a competition event in which
the ligand supersedes the two receptors bound to each other
and thereby changes their relative orientation. This concept
would suggest that mutations in the ligand-binding epitope
of the receptor would not only affect ligand binding but also
inhibit the formation of preformed dimers which might be a
prerequisite for efficient signal initiation. Such an interest-
ing case has been observed in the class of complex receptors
which now will be discussed.
2.4. ‘Complex’ receptors
The ‘complex’ receptors consist of more domains than
needed for ligand binding and can therefore be divided into
two parts, one responsible for ligand binding and the other
involved in transmitting the signal into the cell. One para-
digmatic conclusion derived from the studies of the GH/
GHR complex was that generally, cytokines are recognized
by their cognate receptors at sites equivalent to site I and site
II of GH [3,4]. This paradigm does not hold true for IL-6 type
cytokines and their ‘complex’ receptors gp130, LIFR and
OSMR. The existence of three distinct receptor binding
epitopes has been clearly demonstrated for IL-6, IL-11 and
CNTF. In analogy to GHR that occupies site I (end of AB-
loop, C-terminal D-helix) and site II (A/C-helix) of the GH,
the cognate a-receptor is located at site I and the common
signal transducer gp130 at site II of these cytokines. A third
h-receptor binding epitope (site III) is not present on GH and
is occupied by a second gp130 molecule (IL-6, IL-11) or
serves as a specific LIFR binding site on CNTF [7,10–12].
Site III consists of the C-terminal A-helix, the N-terminal
AB-loop, the BC-loop with adjacent amino acid residues, the
C-terminal CD-loop and the N-terminal D-helix [7,10].
Based on mutagenesis studies in combination with molecular
modelling studies, it has been shown that the sites I and II of
the IL-6 type cytokines exclusively interact with the corre-
sponding CRH of the involved receptors, whereas site III is
utilizing the Ig-like domain of the ‘complex’ receptors. Thus,
the ‘complex’ receptors have two distinct binding regions.
These data, mostly derived from biochemical studies, have
been confirmed by the recently solved X-ray structure of the
viral IL-6 molecule in complex with two gp130 molecules.
In this complex, the CRH of one gp130 molecule is indeed
bound to the ligand via its CRH to site II and the second
gp130 molecule uses its Ig-like domain to bind to site III of
the viral IL-6 [6,8,9]. Since one gp130 molecule has two
distinct binding sites, two gp130 molecules are able to bind
two ligands in a symmetrical arrangement as seen in the X-
ray structure [6] depicted schematically in Fig. 4A. But most
interestingly, only one of these two symmetrical binding sites
per gp130 molecule is needed to induce signal transduction.
This has been shown by Pflanz et al. who used two mutants
of gp130 that either lack the Ig-like domain or contain a
distinct mutation within the CRH. Both mutants were to be
unable to induce IL-6 signal transduction [37]. After co-
transfection of both inactive mutations IL-6 bioactivity was
restored (Fig. 4B). Since the combination of the two gp130-
muteins is able to bind only one IL-6/IL-6R complex, the
formation of a tetrameric complex, consisting of one IL-6,
one IL-6R and two gp130 molecules is sufficient for bio-
logical activity. In addition, the same authors showed that the
two epitopes sequentially co-operate upon IL-6-induced
receptor activation and combining the two mutations restores
the high affinity of ligand binding [37]. How can two intact
binding epitopes cooperate within two different molecules?
One attractive explanation might be the formation of pre-
J. Gro¨tzinger / Biochimica et Biophysica Acta 1592 (2002) 215–223 219
formed dimers. In analogy to the situation of the EpoR,
where same epitopes are responsible for dimerization as well
as ligand binding, in the case of gp130 the Ig-like domain of
one gp130 would interact with the CRH of the second and
vice versa (Fig. 4C). Therefore, mutation in the CRH or
removal of the Ig-like domain would affect both interaction
sites and thereby prevent dimerization, whereas a combina-
tion of the two mutated gp130 molecules would still allow
the formation of dimers by the combination of the two intact
epitopes present in each molecule. In the case of the hetero-
dimeric receptor complex gp130/OSMR, it has been shown
that this complex exists as a preformed dimer on the cell
surface by co-immunoprecipitation experiments [38]. Since
these cells were not transfected with the corresponding
cDNAs, the observed dimers cannot be an experimental
artifact due to overexpression. Furthermore, mutations
within the CBM of gp130 abrogate signalling by IL-6 but
not by LIF or OSM [39,40]. In the case of IL-6, these
mutations might be able to interfere with the formation of
a symmetric preformed dimeric gp130 but not within the
preformed asymmetric gp130/LIFR or gp130/OSMR.
In contrast to the ‘simple’ receptors, the ‘complex’ ones
have more than one epitope for the interaction with the
ligand. To make the situation even more ‘complex,’ they
also have domains that are not involved in ligand binding.
The signal transducing subunits of the IL-6 type family of
cytokines, namely gp130, LIFR and OSMR, contain three
membrane-proximal fibronectin type III domains (see Fig.
2), an architecture that is also seen in the G-CSFR. Muta-
tional studies on soluble and membrane bound gp130 shed
light on the role that these domains may play. As two
strategies, deletion and substitution mutants have been
created to study their contribution in signal transduction
[41,42].
Deletion of any of these domains in the soluble protein
had no impact on the binding characteristics [42]. In the
membrane bound form, the results were contradictory. All
these muteins were not able to initiate signal transduction,
but more surprisingly, some of them were no longer able to
bind the ligand. Deletions of the fourth and sixth domain led
to a complete loss of binding, whereas deletion of the fifth
revealed some residual binding [42]. Therefore, these
domains seem to be necessary to position the upper domains
in a specific way that enables these domains to bind the
ligand. Another study used chimeras of gp130 and G-CSFR,
in which the three membrane-proximal fibronectin type III-
like domains were exchanged between the two receptors:
(GR-FNIII)gp130, which contains the membrane-proximal
FNIII modules of G-CSFR, and its complement the chimera
(gp130–FNIII)GR [41]. Both chimeras were able to bind
their corresponding ligands, demonstrating that the three
membrane-distal domains, which are responsible for recog-
nising the ligands, are presented in an appropriate orienta-
tion. This picture completely changed when these chimeras
were tested on their ability to induce biologically activity.
Whereas cells transfected with the cDNA coding for the
chimera (gp130–FNIII)GR were fully responsive to G-CSF,
cells transfected with the other chimera did not respond to
the IL-6/IL-6R complex, but to an agonistic anti-gp130
monoclonal antibody. Since these cells were also expressing
the LIFR, the authors asked the question whether a hetero-
dimer of (GR-FNIII)gp130/LIFR is able to induce LIF
dependent signalling. This heterodimeric receptor failed to
bind to LIF with high affinity and the cells did not respond
to LIF.
A paper of Kurth et al. [42] utilized a similar strategy of
substitution. The authors exchanged only one of the FNIII
domains, namely D5, in gp130 by the corresponding G-
Fig. 4. (A) Schematic representation of the (gp130/viral IL-6)2 complex as solved by X-ray crystallography [6]. (B) Schematic representation of the IL-6/IL-6R/
(gp130)2 complex in which both gp130 molecules are mutated, with molecules either lacking the Ig-like domain (DD1) or carry mutations in the CRH (marked
by *). (C) Pre-formed gp130 dimer in which the Ig-like domain of one gp130 would interact with the CRH (D2,D3) of the second and vice versa.
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CSFR domain. Surprisingly, in cells overexpressing this
mutein, the activation of this chimera became ligand inde-
pendent, suggesting this domain may play a role in the
activation of the receptor.
Taken together, the above described results show clearly
that the three membrane-proximal domains play a pivotal
role in the transmission of the signal, but it is unable to be
explained by a unique model. If dimerization is needed but
not sufficient, and the three membrane-proximal FNIII
domains are important for receptor activation, the question
that remains is whether we can learn something about their
activation mechanism from receptors which are covalently
linked dimers.
2.5. The insulin receptor as a template for cytokine
receptors?
The INSR can be regarded as a covalently linked homo-
dimer, since division into an a- and h-chain is a proteolytic,
posttranslational process. Like gp130, the INSR can be
divided into two regions, one for binding the ligand (L1-
CR-L2), the other one responsible for signal transmission.
Like in gp130, the latter consists of three membrane-
proximal FNIII domains (Fig. 2). Interestingly, the quater-
nary structure of the insulin receptor bound to one insulin
molecule has recently been solved by cryo-electron micro-
scopy [43]. Although the reported structure has no atomic
resolution, the overall shape of the whole receptor, the
location and relative orientation of the different domains
could be deduced (for review see Ref. [44]). Surprisingly,
this study revealed that the receptor molecule has the shape
of a globular protein instead of being clearly divided into a
extra- and intracellular part divided by the membrane (Fig.
5A). The L2 domain, which is involved in ligand binding,
and the two membrane-proximal FNIII domains seem to be
in direct contact with the intracellular kinase domain. This
direct contact might suggest that the extracellular and intra-
cellular parts are able to communicate directly which each
other and that the information need not be transmitted
through a transmembrane region. In fact, the two hydro-
phobic amino acid segments of about 25 residues that were
supposed to span the membrane as helices are far apart from
each other and are unable to come into contact. The two
membrane-proximal FNIII domains (Fn2 and Fn1), lying
parallel to the membrane, are described by the authors as
one part of a pontoon. In between the two pontoons, the
ligand binding domains are mounted with the help of the
third FNIII domain (Fn0). In a recent review, the same
authors discuss details about the mechanism by which this
topology might be used to transmit the signal to the kinase
domains [44]. Because all these receptors can be divided
into two regions, one for the specific binding of the ligand,
and a second, membrane-proximal region consisting of three
FNIII domains. The latter can be regarded as a dance floor
on which each dancer performs their own specific choreog-
raphy. Nevertheless, the mechanism by which the noise of
the dancing steps is transmitted through the floor is the
same.
Can the above described results on deletion and sub-
stitution mutants of gp130 be explained by a model which
assumes that the overall topology of gp130 and INSR is the
same? The deletion studies can be explained easily. Remo-
val of one of the FNIII domains in the soluble forms of
gp130 would have no influence on the orientation of the
ligand-binding domains, since they are free to rotate and
translate in solution. The situation is different when these
constructs are fixed to the membrane. Now, the remaining
membrane-proximal domains direct the ligand-binding
domains into different orientations and thereby prevent the
correct interaction with the ligand. Results obtained with the
chimeric receptor constructs fit also into this picture. With
both molecules, the dance floor is built up by two times
Fig. 5. Quaternary structure of the insulin receptor. (A) Full-mass representation of the insulin receptor structure as determined by cryo-electron microscopy
[43]. (B and C) Simplified schematic of the change in domain orientation during activation of the insulin receptor. (B) Inactive configuration: The ectodomains
of the a-subunits each with two different insulin binding sites and one blocking cam touching the Fn2 domain, thereby keeping the tyrosine kinases (TK)
separated. (C) Active configuration: The blocking cams has been rotated allowing the h-subunits to move closer to the center of the ectodomain and the
activation loop (A-loop) of each kinase is positioned for transphosphorylation. (This figure is taken from Ref. [44] with kind permission of the American
Chemical Society).
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three FNIII domains of the same molecule, either G-CSFR
or gp130 and is therefore functional, as observed for G-CSF
and the agonistic anti-gp130 antibody. The situation for IL-6
might be different since the activating ligand is not IL-6
alone but the IL-6/IL-6R complex. Due to the dense packing
of the domains in an INSR-structure based gp130 model, it
must be assumed that the IL-6R has numerous contacts with
gp130, even with the membrane-proximal domains. Replac-
ing these by the corresponding domains of G-CSFR, this
interaction may prevent complex formation. Since the viral
IL-6 is interacting directly with gp130, without the help of a
specific a-receptor [45,46], it should be able to induce
signal transduction via this chimeric receptor.
In case of LIF as the ligand, the dance floor would be a
combination of the GCFSR–FNIII domains and the corre-
sponding domains of the LIFR, a heterodimeric combination
that has never been observed and therefore might not be able
to dimerize.
The fifth domain seems to play a special role. As
described above, the membrane bound deletion mutant is
still able to bind the ligand, but is unable to initiate the
signalling cascade. Replacement of this domain by the
corresponding one of the G-CSFR, at least in cells over-
expressing this chimera, leads to constitutive activation.
This result again suggests that preformed dimers exist and
the exchange of the fifth domain results in a topological
change of the domains which corresponds to the activated
receptor (Fig. 5B and C). In the INSR, the fifth and sixth
domains are in a rod-like orientation, thereby representing
one half of the pontoon, suggesting strong interactions
between them. Furthermore, the sixth domain is directly
involved in the activation mechanism, since the cysteine-
rich domain touches it. This contact is thought to transmit
the information of ligand binding to the dance floor, thereby
permitting the approach of the tyrosine kinases (Fig. 5B and
C). Replacing the fifth domain in gp130 by the correspond-
ing one of G-CSFR would weaken the connection between
the fifth and sixth domain, thereby relaxing the stiffness
between them and may thereby allow the intracellular parts
to approach and induce signal transduction.
The contribution of the intracellular associated JAK
kinases to the formation of dimeric receptors has not been
examined so far, but may have an important impact on the
activation mechanism. Since the extracellular part acts in
this model as a gate that has to be opened by the ligand, the
prediction would be that removal of the whole extracellular
part, but not of the transmembrane region, will lead to a
constitutively active receptor.
2.6. The tasks ahead
Much of what has been suggested above is of a hypo-
thetical nature. Further experimental evidence for the sug-
gested models is needed. So far, the existence of a pre-formed
dimer of gp130 on the cell surface has not been shown
unambiguously, although there are many indications for their
existence. The quaternary structure of the INSR might be
used as a template for the domain organization of the signal-
transducing receptor subunits of the IL-6 type cytokines,
especially gp130, and may lead to a unique explanation of
the so far published experiments about the role of the FNIII
domains. The INSR shows a negative co-operativity upon
insulin binding and seems to be more than a simple on/off
switch. Again, there are hints that gp130 behaves the same in
the case of its IL-6/IL-6R induced activation, but detailed
studies to prove this point are not yet available. Nevertheless,
the suggested analogy has to be proven by more experimen-
tal data, but may guide future work to establish an activation
mechanism for these receptors.
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